CRA inhibits the growth of human tumor xenografts in vivo.

Slides:

Advertisements

Similar presentations

A, Effect of folate-FITC (500 nmol/kg, 5 days/week) and/or sunitinib (20 mg/kg daily) therapy on the growth of M109 tumors in Balb/c mice. A, Effect of.

Advertisements

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.

Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

25(OH)D and 1,25(OH)2D perfusion treatment effect on cancer-related markers: IF stains illustrating expression levels for Ki-67 (A), cyclin D1 (B), ErbB-2.

AZD7762 abrogated the G2 checkpoint in a novel hollow fiber assay.

Effects of SC144 on in vivo ovarian tumor.

The STM1787 promoter in Salmonella is rapidly activated in vivo by the tumor microenvironment. The STM1787 promoter in Salmonella is rapidly activated.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.

Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.

Activity of MAC-321 (i. v. and p. o

In vivo growth inhibition elicited by afatinib and GSK in a CLU–NRG1-rearranged PDX mouse model. In vivo growth inhibition elicited by afatinib.

ONC201 activates the ISR. ONC201 activates the ISR. (A) Western blotting analysis for ATF4, CHOP, ATF3, and TRB3 on lysates from HCT116 cells cultured.

CO-1686 does not inhibit WT EGFR signaling in vivo and is active in EGFR-mutant transgenic mouse lung cancer models. CO-1686 does not inhibit WT EGFR signaling.

Antitumor activity of bevacizumab in PDX models was not correlated with the ratio of human and mouse VEGF-A of the models. Antitumor activity of bevacizumab.

TFAP2A knockdown inhibits tumor growth in vivo.

Antitumor immunity caused by DS-8201a.

Skin tumor size following ligand activation of PPARβ/δ and inhibition of COX2. Skin tumor size following ligand activation of PPARβ/δ and inhibition of.

Effect of HA on hematopoietic recovery in tumor-bearing mice.

PTENP1 sensitizes renal cancer cells to chemotherapy.

Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.

NSG mice transplanted with human primary ALK-positive ALCL tumor grafts were administered either doxorubicin, 10 mg/kg i.v. or CEP orally, 100 mg/kg,

Effects of DPM treatment on tumor volume, tumor mass, and pulmonary metastasis at experimental end point. Effects of DPM treatment on tumor volume, tumor.

In vivo growth-inhibitory effect of perifosine on bevacizumab-resistant CCC. A, the effect of bevacizumab (BEV) on CCC growth in vivo. In vivo growth-inhibitory.

PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant p53 in vivo. PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant.

CAT displays very high in vivo stability as exemplified by a rat PK study. CAT displays very high in vivo stability as exemplified by a rat.

Accelerated metastasis spread in tumor-bearing mice treated with paclitaxel and anakinra. Accelerated metastasis spread in tumor-bearing mice treated with.

Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c

The effect of IAA on tumor growth in an SK-MEL-28 xenograft model.

Antitumor activity of MLN8237 against TNBC patient-derived tumor xenografts (PDTX) in vivo. Antitumor activity of MLN8237 against TNBC patient-derived.

Cisplatin plus PTUPB decreases proliferation and angiogenesis but increases apoptosis as determined by immunohistochemical (IHC) analysis. Cisplatin plus.

Antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against xenograft models sensitive.

PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. A, 4T1/HAS3.

Pharmacological targeting of CDs promotes response to KRASG12C inhibition in vivo. Pharmacological targeting of CDs promotes response to KRASG12C inhibition.

Angiogenesis in tumors formed by cells varying in the expression of CXCR2. Angiogenesis in tumors formed by cells varying in the expression of CXCR2. A,

Curcumin enhances effects of bortezomib to inhibit angiogenesis in multiple myeloma tumor samples. Curcumin enhances effects of bortezomib to inhibit angiogenesis.

GA reduces the growth of Caki-1 tumor xenografts.

Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth and metastasis. Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth.

Antitumor effects of celastrol in vitro and in vivo.

Immunohistochemical analysis of dUTPase in human breast adenocarcinoma

Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ) in vivo. Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ)

Visualization of tumor vasculature using anti-CD31 immunohistochemistry. Visualization of tumor vasculature using anti-CD31 immunohistochemistry. Micrographs.

Xenograft regrowth studies.

Pharmacodynamic evaluation of VT-464 and ABI in MR49F xenograft model.

Three-day biodistribution of 125I-labeled chTNT-3 administered at (A) 1, 2, or 3 days after pretreatment with VP-16 (30 mg/kg) in MAD109 bearing BALB/c.

Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.

Effect of the crystal form and solid dispersion preparations of KRN633 on the growth of human tumor xenografts in mice. Effect of the crystal form and.

A, tumor growth studies in H1975 tumor–bearing mice.

miR-100 suppresses bladder cancer cell growth in vitro and in vivo.

NT157 treatment inhibits LNCaP xenograft growth and delays castration-resistant progression. NT157 treatment inhibits LNCaP xenograft growth and delays.

Activity of a chemically modified miR-21 inhibitor in human bladder cancer xenografts. Activity of a chemically modified miR-21 inhibitor in human bladder.

Determination of MTD for romidepsin and pralatrexate and associated antitumor activity. Determination of MTD for romidepsin and pralatrexate and associated.

Effect of CDV on human SF7796 xenografts in vivo.

Mean weight change from original weight of (a) BALB/c (b) DBA/2 mice after one (♦) or two (▴) injections of 10 mg/kg and one (▪) or two (×) injections.

Impact of eNOS expression and treatment with GSNO on prostate tumor growth. Impact of eNOS expression and treatment with GSNO on prostate tumor growth.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

SW620 xenografts treated with combination siKRAS+siPIK3CA/B.

RhuαVEGF and rhuαVEGF/paclitaxel mediated growth inhibition in an androgen-independent prostate cancer xenograft model. rhuαVEGF and rhuαVEGF/paclitaxel.

Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer cell growth. Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer.

BMX inhibition suppresses the growth of CRPC cells in vitro and in vivo. BMX inhibition suppresses the growth of CRPC cells in vitro and in vivo. A, CWR22RV1.

TAE-684 effectively inhibits the growth of H3122 in vivo.

PDL192 and inhibit the growth of xenograft tumors.

A, antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against “sensitive” Ewing.

Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC xenografts. Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC.

CPI-444 synergizes with anti–PD-L1 and anti–CTLA-4 treatment.

In vivo effect of KIN-193 on PTEN-deficient tumors.

BH3-targeted inhibitors drive specific resistance in human cell lines, which can be overcome with alternating or combining inhibitors. BH3-targeted inhibitors.

Curative effect of W+T treatment in vivo.

Presentation transcript:

CRA-026440 inhibits the growth of human tumor xenografts in vivo. CRA-026440 inhibits the growth of human tumor xenografts in vivo. The growth of tumors over time is plotted in (A) U937 histiocytic tumor xenograft model (vehicle alone, ♦; 100 mg/kg, ×; 50 mg/kg, ▴; 25 mg/kg, ▪), (B) HCT 116 colon tumor xenograft model (vehicle alone, ♦; 150 mg/kg, ◊; 100 mg/kg, ×; 75 mg/kg, ▴; 50 mg/kg, ▪), (C) HCT116 colon tumor xenograft model (vehicle alone, ♦; 50 mg/kg qdx4/wk, ▪; 67 mg/kg qdx3/wk, □; 100 mg/kg qdx2/wk, ×; 100 mg/kg Monday + Friday/wk, ◊), (D) HCT 116 colon tumor xenograft model (vehicle alone, ♦; 25 mg/kg, ▴; 50 mg/kg, ▪; Avastin 25 mg/kg, ×; Avastin + CRA-026440 at 25 mg/kg, ▵; Avastin + CRA-026440 at 50 mg/kg, □). Ki67 immunohistochemical analysis: (E) HCT 116 xenograft tumors with three daily i.v. treatment of vehicle, (F) HCT 116 xenograft tumors with three daily i.v. treatment of CRA-026440 at 100 mg/kg. Error bars were calculated as described in Materials and Methods. *, P < 0.05; **, P < 0.01. Z. Alexander Cao et al. Mol Cancer Ther 2006;5:1693-1701 ©2006 by American Association for Cancer Research